Last reviewed · How we verify

Dotarem (gadoterate meglumine)

Guerbet · Phase 3 active Small molecule

Dotarem (gadoterate meglumine) is a Gadolinium-based contrast agent Small molecule drug developed by Guerbet. It is currently in Phase 3 development for Contrast-enhanced MRI of the brain, spine, and body in adults and pediatric patients, Contrast-enhanced MRI for detection and characterization of lesions in various organs. Also known as: Dotarem.

Gadoterate meglumine is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.

Gadoterate meglumine is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for Contrast-enhanced MRI of the brain, spine, and body in adults and pediatric patients, Contrast-enhanced MRI for detection and characterization of lesions in various organs.

At a glance

Generic nameDotarem (gadoterate meglumine)
Also known asDotarem
SponsorGuerbet
Drug classGadolinium-based contrast agent
TargetWater proton relaxation (T1 relaxation time)
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhasePhase 3

Mechanism of action

Gadoterate meglumine is a macrocyclic gadolinium chelate complex that distributes into the extracellular space following intravenous administration. The paramagnetic gadolinium ion increases the relaxivity of nearby water molecules, causing signal enhancement on T1-weighted MRI sequences. This allows improved visualization and characterization of tissues and lesions during diagnostic imaging.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dotarem (gadoterate meglumine)

What is Dotarem (gadoterate meglumine)?

Dotarem (gadoterate meglumine) is a Gadolinium-based contrast agent drug developed by Guerbet, indicated for Contrast-enhanced MRI of the brain, spine, and body in adults and pediatric patients, Contrast-enhanced MRI for detection and characterization of lesions in various organs.

How does Dotarem (gadoterate meglumine) work?

Gadoterate meglumine is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.

What is Dotarem (gadoterate meglumine) used for?

Dotarem (gadoterate meglumine) is indicated for Contrast-enhanced MRI of the brain, spine, and body in adults and pediatric patients, Contrast-enhanced MRI for detection and characterization of lesions in various organs.

Who makes Dotarem (gadoterate meglumine)?

Dotarem (gadoterate meglumine) is developed by Guerbet (see full Guerbet pipeline at /company/guerbet).

Is Dotarem (gadoterate meglumine) also known as anything else?

Dotarem (gadoterate meglumine) is also known as Dotarem.

What drug class is Dotarem (gadoterate meglumine) in?

Dotarem (gadoterate meglumine) belongs to the Gadolinium-based contrast agent class. See all Gadolinium-based contrast agent drugs at /class/gadolinium-based-contrast-agent.

What development phase is Dotarem (gadoterate meglumine) in?

Dotarem (gadoterate meglumine) is in Phase 3.

What are the side effects of Dotarem (gadoterate meglumine)?

Common side effects of Dotarem (gadoterate meglumine) include Gadolinium retention in tissues, Nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, Injection site reactions, Headache, Nausea.

What does Dotarem (gadoterate meglumine) target?

Dotarem (gadoterate meglumine) targets Water proton relaxation (T1 relaxation time) and is a Gadolinium-based contrast agent.

Related